ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC increased its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 15.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 156,802 shares of the specialty pharmaceutical company’s stock after acquiring an additional 20,900 shares during the period. Renaissance Technologies LLC owned approximately 0.75% of ANI Pharmaceuticals worth $9,985,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Innealta Capital LLC acquired a new stake in ANI Pharmaceuticals in the second quarter valued at $65,000. Ridgewood Investments LLC purchased a new position in ANI Pharmaceuticals during the 2nd quarter valued at about $85,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals during the first quarter worth about $106,000. ADAR1 Capital Management LLC purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at about $132,000. Finally, Clear Street Markets LLC acquired a new stake in shares of ANI Pharmaceuticals in the fourth quarter valued at approximately $140,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Raymond James increased their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. HC Wainwright reiterated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Truist Financial restated a “hold” rating and issued a $60.00 target price (down from $80.00) on shares of ANI Pharmaceuticals in a report on Wednesday, September 11th. Finally, StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $78.80.

ANI Pharmaceuticals Stock Up 0.7 %

ANIP opened at $60.08 on Tuesday. ANI Pharmaceuticals, Inc. has a 12 month low of $48.20 and a 12 month high of $70.81. The business has a 50-day moving average of $61.00 and a two-hundred day moving average of $63.64. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. The stock has a market capitalization of $1.26 billion, a price-to-earnings ratio of 37.55 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.07. The firm had revenue of $138.00 million during the quarter, compared to the consensus estimate of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. ANI Pharmaceuticals’s revenue was up 18.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.06 earnings per share. On average, research analysts expect that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 14,257 shares of the business’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $63.16, for a total transaction of $900,472.12. Following the completion of the sale, the chief operating officer now owns 635,363 shares of the company’s stock, valued at $40,129,527.08. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, SVP Chad Gassert sold 20,000 shares of ANI Pharmaceuticals stock in a transaction on Monday, July 1st. The shares were sold at an average price of $63.44, for a total transaction of $1,268,800.00. Following the transaction, the senior vice president now owns 193,226 shares in the company, valued at approximately $12,258,257.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Muthusamy Shanmugam sold 14,257 shares of the stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $63.16, for a total value of $900,472.12. Following the completion of the sale, the chief operating officer now owns 635,363 shares of the company’s stock, valued at $40,129,527.08. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,007 shares of company stock valued at $2,911,790. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.